tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of David Lebowitz, 145 are a BUY (61.97%), 56 are a HOLD (23.93%), 33 are a SELL (14.1%).
Analyst David Lebowitz, currently employed at CITI, carries an average stock price target met ratio of 62.08% that have a potential upside of 35.64% achieved within 225 days.
David Lebowitz’s has documented 417 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals at 01-Sep-2025.
Analyst best performing recommendations are on PLRX (PLIANT THERAPEUTICS ).
The best stock recommendation documented was for PLRX (PLIANT THERAPEUTICS ) at 3/4/2025. The price target of $1.5 was fulfilled within 1 day with a profit of $0.12 (8.7%) receiving and performance score of 86.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$7.5
$4.67 (165.02%)
$7.5
6 months 7 days ago
(03-Apr-2025)
14/29 (48.28%)
$5.73 (323.73%)
327
Buy
$4
$1.17 (41.34%)
$2
2 years 4 months 10 days ago
(30-May-2023)
2/12 (16.67%)
$2.96 (284.62%)
753
Buy
$1
$-1.83 (-64.66%)
$8
3 years 6 months 10 days ago
(31-Mar-2022)
1/2 (50%)
$0.33 (49.25%)
311
Buy
$7
3 years 6 months 10 days ago
(31-Mar-2022)
3/6 (50%)
$5.37 (107.92%)
411
Hold
$2
$-0.83 (-29.33%)
$6
3 years 6 months 10 days ago
(30-Mar-2022)
3/11 (27.27%)
$1.28 (177.78%)
467
Which stock is David Lebowitz is most bullish on?
Which stock is David Lebowitz is most reserved on?
What Year was the first public recommendation made by David Lebowitz?
